Selective small-molecule inhibitors of the transcription-associated cyclin-dependent kinases were shown to suppress HIV-1 proviral expression, and inhibition of the Mediator kinases CDK8/CDK19 (Senexin A, BRD6989) uniquely imposed a latent state that persisted for days after drug removal, identifying CDK8/19 as candidate "block and lock" targets for a functional HIV-1 cure. The open issues raised by the source work remain unresolved: (1) the molecular mechanism by which CDK8/19 inhibition establishes durable latency at the HIV-1 long terminal repeat is unknown — the source infers "modification of transcription factors and/or chromatin organization associated with HIV-1 provirus that persists following removal of the inhibitor" without identifying it; (2) the paradox that CDK7 inhibition increases the proportion of cells becoming infected by HIV-1 while enriching for latent provirus reflects, in the source's words, a function of TFIIH for HIV-1 transcription that has not been characterized; (3) the source notes that no human trials with latency-enforcing compounds have been performed, so the in vivo efficacy, pharmacokinetics, and safety of CDK8/19 inhibitors as latency-promoting agents remain untested; and (4) the source proposes that persistent CDK8/19-mediated silencing "could be exploited with synergistic latency promoting agents," but combinations with other latency-promoting agent classes (Tat inhibitors, XPB degraders) are unexplored. Durability of the repressive state under physiological T-cell receptor stimulation, as opposed to the pharmacological PMA/ionomycin activation used in the source, and possible dependence of durable silencing on proviral integration context remain recognized untested gaps, though the source did not pose them as open questions.

Background

Infection with HIV-1 persists lifelong because the virus integrates a DNA copy of its genome (the provirus) into the chromosomes of long-lived CD4+ T cells, where it can persist in a transcriptionally silent state termed latency. Combination antiretroviral therapy (ART) blocks new replication but cannot eliminate this latent reservoir, and viremia rebounds within weeks of treatment interruption. Two complementary cure paradigms target the reservoir: "shock and kill" attempts to reactivate latent provirus for immune clearance, while "block and lock" seeks to enforce a deep, durable latency so that viral expression stays suppressed even without ART, using drugs called latency-promoting agents (LPAs). The leading experimental LPA is the Tat inhibitor didehydro-cortistatin A, which delays viral rebound in humanized mice.

Transcription of the provirus is driven by the viral long terminal repeat (LTR) promoter and depends on host RNA polymerase II and its regulatory kinases. The viral transactivator Tat recruits the elongation factor P-TEFb (the CDK9/cyclin T1 pair, where CDK9 is cyclin-dependent kinase 9) to the nascent TAR RNA (the transactivation-response stem-loop at the start of each viral transcript), releasing paused polymerase and creating a strong positive feedback loop. The general transcription factor TFIIH, whose kinase subunit is CDK7 (with cyclin H and MAT1, forming the CDK-activating kinase module), is recruited to the LTR and is rate-limiting for proviral reactivation; the drug spironolactone enforces latency by degrading the XPB subunit of TFIIH, though expression rebounds immediately upon its withdrawal. CDK8 and CDK19 are paralogous kinases of the Mediator complex's kinase module, a regulatory complex that fine-tunes transcription by phosphorylating transcription factors such as NF-κB (nuclear factor kappa B), β-catenin, and STAT proteins (signal transducers and activators of transcription). Whether these Mediator kinases control HIV-1 transcription was itself contested: siRNA depletion studies concluded HIV transcription is independent of Mediator kinases, while inhibitor studies found the opposite.

Horvath, Brumme and Sadowski (bioRxiv 2023; published in Antimicrobial Agents and Chemotherapy 68(3):e01072-23, 2024) directly compared highly selective inhibitors of CDK7 (YKL-5-124), CDK9 (LDC000067), and CDK8/19 (Senexin A) across Jurkat T-cell-derived latency reporter lines (JLat10.6, JLat9.2, JLatA72, and mdHIV clonal lines), newly infected T cells, and peripheral blood mononuclear cells (PBMCs, the mixed immune-cell fraction of blood) from three ART-suppressed people living with HIV-1. All three inhibitor classes suppressed proviral expression at non-toxic concentrations, but CDK7 inhibition caused cell cycle arrest, CDK9 inhibition gave only immediate-rebound latency upon washout, and CDK8/19 inhibition induced a latent state that persisted for more than a week after drug removal, with synergy between CDK9 and CDK8/19 inhibitors. The authors identified CDK8/CDK19 as candidate "block and lock" targets and laid out the unresolved issues that define this problem. A companion study (Journal of Virology 97(9):e0092323, 2023) showed that Senexin A impairs recruitment of RNA polymerase II to the LTR, that CDK8 gene knockout does not fully mimic kinase inhibition, and that CDK8/19 effects are absent in HEK293T and HeLa cells — reconciling the earlier negative siRNA results in those cell types — but the molecular pathway that maintains latency after inhibitor removal, and the translational viability of the approach, remain undefined.

Problem Statement

Horvath, Brumme and Sadowski (Antimicrobial Agents and Chemotherapy 68(3):e01072-23, 2024) established that selective inhibition of the Mediator kinases CDK8/CDK19 suppresses HIV-1 proviral expression and induces a latent state that persists after inhibitor removal, in contrast to CDK9 inhibition, which rebounds immediately. The open problem, as posed by that work and left untouched by the 2024-2026 literature, is to establish whether CDK8/19 inhibition can serve as a mechanistically understood, durable, and clinically tolerable "block and lock" strategy for HIV-1. The source work explicitly raises the following open questions. (1) Molecular mechanism: identify the specific pathway — altered phosphorylation of transcription factors acting at the LTR (such as NF-κB, β-catenin, or STAT proteins), changes in histone modifications, or nucleosome repositioning — by which CDK8/19 inhibition creates a proviral chromatin/transcription-factor state that persists after the inhibitor is withdrawn, in the source's framing a "modification of transcription factors and/or chromatin organization associated with HIV-1 provirus that persists following removal of the inhibitor," resolving why CDK8 gene ablation and kinase inhibition produce overlapping but non-identical phenotypes. (2) TFIIH paradox: explain why pharmacological CDK7 inhibition increases the overall rate of HIV-1 infection while enriching for latent provirus, and characterize the corresponding function of the TFIIH complex in HIV-1 transcription that, in the source's words, "has not been characterized." (3) Translational validation: the source notes that no human trials with latency-enforcing compounds have been performed; determine the in vivo efficacy, pharmacokinetics, and safety of CDK8/19 inhibitors as LPAs on the path toward clinical evaluation. (4) Combination therapy: test the source's proposal that persistent CDK8/19-mediated silencing could be exploited with synergistic latency-promoting agents — Tat inhibitors such as didehydro-cortistatin A, or XPB degraders such as spironolactone — to maintain suppression of proviral expression following discontinuation of ART, building on the observed synergy between CDK9 and CDK8/19 inhibitors. Each of these four questions is posed as an independent open problem, and the others may remain open. For (3) and (4), the necessary in vivo data do not yet exist. In addition, the durability of CDK8/19-induced latency under physiological T-cell receptor stimulation (rather than the PMA/ionomycin activation used in the source) and its possible dependence on proviral integration context are recognized untested gaps that the source did not pose as open questions; they are context for the problem.

References

  1. Horvath RM, Brumme ZL, Sadowski I. Small molecule inhibitors of transcriptional cyclin-dependent kinases impose HIV-1 latency, presenting "block and lock" treatment strategies. Antimicrobial Agents and Chemotherapy 68(3):e01072-23 (2024). DOI: 10.1128/aac.01072-23. https://doi.org/10.1128/aac.01072-23
  2. Horvath RM, Brumme ZL, Sadowski I. CDK8 inhibitors antagonize HIV-1 reactivation and promote provirus latency in T cells. Journal of Virology 97(9):e0092323 (2023). DOI: 10.1128/jvi.00923-23. https://doi.org/10.1128/jvi.00923-23
  3. Cary DC, Rheinberger M, Rojc A, Peterlin BM. HIV Transcription Is Independent of Mediator Kinases. AIDS Research and Human Retroviruses 35(8):710-717 (2019). DOI: 10.1089/AID.2019.0039. https://doi.org/10.1089/AID.2019.0039
  4. Mori L, Jenike K, Yeh Y-HJ, Lacombe B, Li C, Getzler AJ, Mediouni S, Cameron ME, Pipkin ME, Ho Y-C, Ramirez BC, Valente ST. The XPB Subunit of the TFIIH Complex Plays a Critical Role in HIV-1 Transcription and XPB Inhibition by Spironolactone Prevents HIV-1 Reactivation from Latency. Journal of Virology 95(4):e01247-20 (2021). DOI: 10.1128/JVI.01247-20. https://doi.org/10.1128/JVI.01247-20
  5. Kessing CF, Nixon CC, Li C, Tsai P, Takata H, Mousseau G, Ho PT, Honeycutt JB, Fallahi M, Trautmann L, Garcia JV, Valente ST. In Vivo Suppression of HIV Rebound by Didehydro-Cortistatin A, a "Block-and-Lock" Strategy for HIV-1 Treatment. Cell Reports 21(3):600-611 (2017). DOI: 10.1016/j.celrep.2017.09.080. https://doi.org/10.1016/j.celrep.2017.09.080
  6. Janssens J, Kim P, Kim SJ, Wedrychowski A, Kadiyala GN, Hunt PW, Deeks SG, Wong JK, Yukl SA. Mechanisms and efficacy of small molecule latency-promoting agents to inhibit HIV reactivation ex vivo. JCI Insight 9(19):e183084 (2024). DOI: 10.1172/jci.insight.183084. https://doi.org/10.1172/jci.insight.183084
  7. Izquierdo-Pujol J, Puertas MC, Martinez-Picado J, Morón-López S. Targeting Viral Transcription for HIV Cure Strategies. Microorganisms 12(4):752 (2024). DOI: 10.3390/microorganisms12040752. https://doi.org/10.3390/microorganisms12040752
  8. Tolomeo M, Cascio A. Block-and-Lock Approaches for HIV Cure: Mechanistic Insights, Challenges, and Emerging Role of CPSF6. International Journal of Molecular Sciences 27(8):3496 (2026). DOI: 10.3390/ijms27083496. https://doi.org/10.3390/ijms27083496
  9. Ling L, Mori LP, Soper A, Yao W, McAuley AT, Leda AR, Spagnuolo RA, Begum N, Kovarova M, Wahl A, Cameron MD, Valente ST, Garcia JV. Combining spironolactone to antiretroviral therapy accelerates HIV decay in humanized mice. Emerging Microbes & Infections 14(1):2589549 (2025). DOI: 10.1080/22221751.2025.2589549. https://doi.org/10.1080/22221751.2025.2589549
  10. Horvath RM, Sadowski I. CBP/p300 lysine acetyltransferases inhibit HIV-1 expression in latently infected T cells. iScience 27(12):111244 (2024). DOI: 10.1016/j.isci.2024.111244. https://doi.org/10.1016/j.isci.2024.111244
  11. González-Jiménez A, Medina I, Alfonso MJ, Vázquez de Aldana CR, Calvo O. RNA polymerase II phosphorylation dynamics: from molecular mechanisms to human disease. RNA Biology 23(1):1-20 (2026). DOI: 10.1080/15476286.2026.2695549. https://doi.org/10.1080/15476286.2026.2695549